Is selection relevant in the evolutionary emergence of drug resistance?

Trends in Microbiology

Volumn 23, Issue 3, 2015, Pages 126-133

  Day, Troy ^a,b   Huijben, Silvie ^c   Read, Andrew F ^b,d  

^a QUEEN S UNIVERSITY   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Antibiotics; Chemotherapy; Evolutionary rescue; Mutant selection window

Indexed keywords

ANTIINFECTIVE AGENT; PYRIMETHAMINE;

ANTIBIOTIC RESISTANCE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL PROTOCOL; DRUG CONCENTRATION; DRUG RESISTANCE; EVIDENCE BASED MEDICINE; FITNESS; HUMAN; INFECTION; MICROBIOLOGICAL PARAMETERS; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; PLASMODIUM CHABAUDI; PLASMODIUM CHABAUDI INFECTION; PREDICTION; PRIORITY JOURNAL; REVIEW; SAMPLING; STATISTICAL ANALYSIS; DRUG EFFECTS; GENETIC SELECTION; GENETICS; MUTATION; REPRODUCTIVE FITNESS;

DRUG RESISTANCE; DRUG RESISTANCE, MICROBIAL; EVOLUTION, MOLECULAR; GENETIC FITNESS; MUTATION; PLASMODIUM CHABAUDI; SELECTION, GENETIC;

EID: 84936986192     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.01.005     Document Type: Review

References (37)

1. zur Wiesch P.A., et al. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 2011, 11:236-247.
2. Chait R., et al. Antibiotic interactions that select against resistance. Nature 2007, 446:668-671.
3. Hegreness M., et al. Accelerated evolution of resistance in multi drug environments. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13977-13981.
4. Pena-Miller R., et al. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biol. 2013, 11:e1001540.
5. Read A.F., et al. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2012, 108:10871-10877.
6. Geli P., et al. One-size-fits-all? Optimizing treatment duration for bacterial infections. PLoS ONE 2012, 7:e29838.
7. Huijben S., et al. Aggressive chemotherapy and the selection of drug resistant pathogens. PLoS Pathog. 2013, 9:e1003578.
8. Ankomah P., Levin B.R. Exploring the coll-aboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:8331-8338.
9. Kouyos R.D., et al. The path of least resistance: aggressive or moderate treatment?. Proc. R. Soc. B 2014, 281:20140566.
10. Olofsson S.K., Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin. Infect. Dis. 2007, 45:S129-S136.
11. Palmer A.C., Kishony R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat. Rev. Genet. 2013, 14:243-248.
12. Huijben S., et al. Chemotherapy, within-host ecology and the fitness of drug resistant malaria parasites. Evolution 2010, 64:2952-2968.
13. Huijben S., et al. The fitness of drug resistant malaria parasites in a rodent model: multiplicity of infection. J. Evol. Biol. 2011, 24:2410-2422.
14. de Roode J.C., et al. Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Malar. J. 2004, 3:33.
15. Otto S.P., Day T. A Biologist's Guide to Mathematical Modeling in Ecology and Evolution 2007, Princeton University Press.
16. Bell G. Evolutionary rescue and the limits of adaptation. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2013, 368:20120080.
17. van den Bosch F., et al. The dose rate debate: does the risk of fungicide resistance increase or decrease with dose?. Plant Pathol. 2011, 60:597606.
18. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 2001, 33:S147-S156.
19. Zhao X., Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 2002, 185:561-565.
20. Drlica K., Zhao X. Mutant selection window hypothesis updated. Clin. Infect. Dis. 2007, 44:681-688.
21. Canton R., Morosini M-I. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol. Rev. 2011, 35:977-991.
22. Andersson D.I., Hughes D. Evolution of antibiotic resistance at non-lethal drug concentrations. Drug Resist. Updat. 2012, 15:162-172.
23. Sindelar G., et al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 2000, 44:3337-3343.
24. Firsov A.A., et al. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 47:1604-1613.
25. Zinner S.H., et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that stimulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob. Chemother. 2003, 52:616-622.
26. Firsov A.A., et al. Abt492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro model. J. Antimicrob. Chemother. 2004, 54:178-186.
27. Tam V.H., et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 2005, 192:420-428.
28. Firsov A.A., et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro model. J. Antimicrob. Chemother. 2006, 58:1185-1192.
29. Olofsson S.K., et al. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J. Antimicrob. Chemother. 2006, 57:1116-1121.
30. Tam V.H., et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 2007, 51:744-747.
31. Firsov A.A., et al. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob. Agents Chemother. 2008, 52:1924-1928.
32. Zhu Y-L., et al. Testing the mutant selection window in rabbits infected with methicillin-resistant Staphylococcus aureus exposed to vancomycin. J. Antimicrob. Chemother. 2012, 67:2700-2706.
33. Zinner S.H., et al. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J. Antimicrob. Chemother. 2013, 68:881-887.
34. Negri M-C., et al. Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob. Agents Chemother. 2000, 44:2485-2491.
35. Gullberg E., et al. Selection of resistant bacteria very low antibiotic concentrations. PLoS Pathog. 2011, 7:e1002158.
36. Hughes D., Andersson D.I. Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr. Opin. Microbiol. 2012, 15:555-560.
37. Baquero F., et al. Evolutionary Biology of Bacterial and Fungal Pathogens 2007, American Society of Microbiology.